Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Lymphoid 3Other 2Head & Neck 2Gastrointestinal 2CNS 2Tumor-Agnostic 1NET 1Gynecologic 1Endocrine 1

Conditions

Lymphoma 3Neoplasms 1

Interventions

Rituximab 1401Cyclophosphamide 1306Vincristine 668Doxorubicin 587Etoposide 527Prednisone 511Cytarabine 486fludarabine 470Methotrexate 445Dexamethasone 413fludarabine phosphate 400Lenalidomide 356Filgrastim 343Bendamustine Hydrochloride 282Radiotherapy 267venetoclax 261ibrutinib 258obinutuzumab 236Peripheral Blood Stem Cell Transplantation 234Melphalan 230Granulocyte Colony-Stimulating Factor 215Bortezomib 204Gemcitabine 202Busulfan 188Whole-Body Irradiation 187Mycophenolic Acid 175Tacrolimus 165Specimen Handling 162Magnetic Resonance Spectroscopy 155Calcium Dobesilate 150

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
RRx-001 × Lymphoid × Clear all
NCT01359982 2024-11-01

DINAMIC

EpicentRx, Inc.

Phase 1 Completed
26 enrolled 11 charts
Lymphoid

Lymphoma, Neoplasms

NCT02518958 2019-11-18

PRIMETIME

EpicentRx, Inc.

Phase 1 Completed
12 enrolled
Lymphoid

Lymphoma

NCT02096341 2016-01-21

A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001

EpicentRx, Inc.

Phase 1 Terminated
2 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡